489 related articles for article (PubMed ID: 16336019)
1. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
Noyes K; Dick AW; Holloway RG;
Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
[TBL] [Abstract][Full Text] [Related]
3. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
Noyes K; Dick AW; Holloway RG
Med Decis Making; 2007; 27(3):327-34. PubMed ID: 17502449
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of pramipexole in Parkinson's disease in the US.
Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
Noyes K; Dick AW; Holloway RG;
Value Health; 2006; 9(1):28-38. PubMed ID: 16441522
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A; Armand C; Murteira S; Cochran J; François C
Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
[TBL] [Abstract][Full Text] [Related]
11. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
Kristiansen IS; Bingefors K; Nyholm D; Isacson D
Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Groenendaal H; Tarrants ML; Armand C
Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Iskedjian M; Einarson TR
Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
[TBL] [Abstract][Full Text] [Related]
20. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Pinter MM; Rutgers AW; Hebenstreit E
J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]